Quilalong, Vance Tyrell P.
HRN: 25-78-26 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/01/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
09/01/2024
09/08/2024
IV
250mg
Q24
Pcap C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes